After a phase 3 push the livmoniplimab plan falters.
ApexOnco Front Page
Recent articles
The company discontinues one of its two KRAS G12D degraders.
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
A quartet of failed tiragolumab trials featured at ESMO over the weekend.
The Stellar-303 trial of zanzalintinib hits, but the discussant asks for more data and flags toxicity.
Full data from Edge-Gastric are presented at ESMO.
The first TUB-040 data come just after Tubulis raised €308m.
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
